| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/08/2003 | EP1272663A2 Polymorphisms in the human cyp2b6 gene and their use in diagnostic and therapeutic applications |
| 01/08/2003 | EP1272652A2 Herpes viruses for immune modulation |
| 01/08/2003 | EP1272646A2 Regulation of human serine racemase enzyme |
| 01/08/2003 | EP1272643A1 Talaromyces emersonii beta-glucanases |
| 01/08/2003 | EP1272642A2 Coffee mannanase |
| 01/08/2003 | EP1272638A2 Drug metabolizing enzymes |
| 01/08/2003 | EP1272636A2 A gene differentially expressed in breast and bladder cancer and encoded polypeptides |
| 01/08/2003 | EP1272634A1 Human ion channel protein and polynucleotides encoding the same |
| 01/08/2003 | EP1272631A2 Regulation of human hm74-like g protein coupled receptor |
| 01/08/2003 | EP1272630A2 Methods and compositions for rna interference |
| 01/08/2003 | EP1272622A1 Method for modification of proteins by transglutaminase |
| 01/08/2003 | EP1272526A1 Enhancement of antibody-mediated immune responses |
| 01/08/2003 | EP1272523A1 Human emr2, a g-protein coupled receptor from the egf-tm7 family |
| 01/08/2003 | EP1272521A2 Regulation of human oatp2-related protein |
| 01/08/2003 | EP1272520A2 Gpcr-proteins and nucleic acids encoding same |
| 01/08/2003 | EP1272518A2 Cd20/ige-receptor like molecules and uses thereof |
| 01/08/2003 | EP1272517A2 Multiprotein-complexes comprising a nmda receptor and uses thereof |
| 01/08/2003 | EP1272516A2 Selective linear peptides with melanocortin-4 receptor (mc4-r) agonist activity |
| 01/08/2003 | EP1272515A2 Immunoregulator |
| 01/08/2003 | EP1272514A1 Dna encoding human vanilloid receptor vr3 |
| 01/08/2003 | EP1272513A2 Neurogenic compositions and methods |
| 01/08/2003 | EP1272512A2 Immunokine composition and method |
| 01/08/2003 | EP1272511A2 Molecules associated with human reproduction |
| 01/08/2003 | EP1272510A2 Pharmacologically active antiviral peptides and methods of their use |
| 01/08/2003 | EP1272509A2 Prion-binding peptidic ligands and methods of using same |
| 01/08/2003 | EP1272506A1 Human aminoacyl-trna synthetase polypeptides useful for the regulation of angiogenesis |
| 01/08/2003 | EP1272502A2 Dna molecules and polypeptides of pseudomonas syringae hrp pathogenicity island and their uses |
| 01/08/2003 | EP1272454A1 Method for synthesis of n- (s)-1-carboxybutyl]-(s)-alanine esters and use in synthesis of perindopril |
| 01/08/2003 | EP1272236A1 Methods and compositions for treating intervertebral disc degeneration |
| 01/08/2003 | EP1272231A1 Compositions and methods for promoting wound healing |
| 01/08/2003 | EP1272230A1 An injectable bone mineral substitute material |
| 01/08/2003 | EP1272225A2 Lipid-based systems for targeting diagnostic agents |
| 01/08/2003 | EP1272222A2 Compositions for drug delivery |
| 01/08/2003 | EP1272221A2 Peptide conjugates for drug delivery |
| 01/08/2003 | EP1272220A1 Formulation for the prevention of cardiovascular disease |
| 01/08/2003 | EP1272215A2 Pharmaceutical preparations comprising modified peptides |
| 01/08/2003 | EP1272212A2 Migraine and vasodilation treatment |
| 01/08/2003 | EP1272211A2 Methods and compositions for treating neoplasms |
| 01/08/2003 | EP1272209A1 Use of crf receptor agonists for the treatment or prophylaxis of diseases, for example neurodegenerative diseases |
| 01/08/2003 | EP1272208A2 Use of vegf and homologues to treat neuron disorders |
| 01/08/2003 | EP1272206A1 Non-mammalian gnrh analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| 01/08/2003 | EP1272186A1 Therapeutic combinations of antihypertensive and antiangiogenic agents |
| 01/08/2003 | EP1272174A1 Combination product comprising a non-steroidal antiandrogen and an egfr tyrosine kinase inhibitor |
| 01/08/2003 | EP1272173A1 Methods for inhibiting angiogenesis and tumor growth |
| 01/08/2003 | EP1272167A1 Hydrophilic/lipophilic polymeric matrix dosage formulation |
| 01/08/2003 | EP1272163A2 Pharmaceutical compositions |
| 01/08/2003 | EP1272161A2 Lipid-based drug delivery systems against parasitic infections |
| 01/08/2003 | EP1272160A2 Lipid-based drug delivery systems for topical application |
| 01/08/2003 | EP1272148A1 Compositions for metabolic protection and repair of lips |
| 01/08/2003 | EP1272044A1 Protein stabilised emulsions |
| 01/08/2003 | EP1218407A4 Uses of kappa-conotoxin pviia |
| 01/08/2003 | EP1140975A4 Stable subtilin and methods of manufacture |
| 01/08/2003 | EP1066061A4 Use of scatter factor to enhance angiogenesis |
| 01/08/2003 | EP1064008B1 Use of at least one protein extract of the moringa genus plant seeds and corresponding cosmetic and/or pharmacological composition |
| 01/08/2003 | EP1005358B1 Use of a neurturin protein product for preventing and treating hearing loss |
| 01/08/2003 | EP0981375B1 Pharmaceutical compositions containing plasma protein |
| 01/08/2003 | EP0859622B1 Extracts of shark cartilage |
| 01/08/2003 | EP0833839B1 Peptidyl heterocycles useful in the treatment of thrombin related disorders |
| 01/08/2003 | EP0833649B1 Methods of preventing or treating allergies |
| 01/08/2003 | EP0817646B1 Methods of treating inflammation and compositions therefor |
| 01/08/2003 | EP0728194B1 In situ modification and manipulation of stem cells of the central nervous system |
| 01/08/2003 | EP0646012B1 WOUND HEALING AND TREATMENT OF FIBROTIC DISORDERS BY TGFbeta-3 |
| 01/08/2003 | EP0607309B1 The regulation of systemic immune responses utilizing cytokines and antigens |
| 01/08/2003 | CN1390257A Transfer compounds, the production and the use thereof |
| 01/08/2003 | CN1390256A Novel protein and DNA thereof |
| 01/08/2003 | CN1390255A Use of disease-associated gene |
| 01/08/2003 | CN1390253A High order nucleic acid based structures |
| 01/08/2003 | CN1390233A Antitumor antibodies, proteins, and uses thereof |
| 01/08/2003 | CN1390232A Human beta-secretase enzyme, inhibitor, and its composition and use |
| 01/08/2003 | CN1390231A Metal-binding compounds and uses thereof |
| 01/08/2003 | CN1390230A Peptides for treatment of erectile dysfunction |
| 01/08/2003 | CN1390220A Kinase inhibitors as therapeutic agents |
| 01/08/2003 | CN1390219A Pyrazolopyrimidines as therapeutic agents |
| 01/08/2003 | CN1390215A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitor |
| 01/08/2003 | CN1390141A Nucleic acid-containing complex |
| 01/08/2003 | CN1390135A Topical treatment of streptococcal infections |
| 01/08/2003 | CN1390134A The use of bacterial phage associated lysing enzymes for the prophylactic and therapeutic treatment of various illnesses |
| 01/08/2003 | CN1390133A Composition for stabilizing corneal tissue during or after orthokeratology lens wear |
| 01/08/2003 | CN1390132A Use of pegylated interferon alpha in melanoma therapy |
| 01/08/2003 | CN1390131A Use of peptide |
| 01/08/2003 | CN1390118A Dextrose and insulin fluid formulation for intravenous infusion |
| 01/08/2003 | CN1389470A Stabilizer for recombinant alpha-interferon liquid |
| 01/08/2003 | CN1389267A Recipe and prepn. of medicine for treating diabetes and ulcer |
| 01/08/2003 | CN1389266A Ointment for treating burns and scalds and its prepn. |
| 01/08/2003 | CN1098462C Method of determining suppressor cell component of immune status of individual and means for carrying out same |
| 01/08/2003 | CN1098274C AZA cyclohexapeptide compounds |
| 01/08/2003 | CN1098103C Pharmaceutical use of sympathetic human white-cell interferon |
| 01/07/2003 | US6504023 DNA encoding type II IL-1 receptors |
| 01/07/2003 | US6504022 Human bad polypeptides, encoding nucleic acids and methods of use |
| 01/07/2003 | US6504014 Tissue specific prodrug |
| 01/07/2003 | US6504011 Recombinantly produced serum albumin is purified in a series of steps, optionally by incubation with an anion-exchange adsorbent, followed by affinity chromatography employing a hydrophobic solid phase and using a water-soluble lipid anion |
| 01/07/2003 | US6504010 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/07/2003 | US6504009 Transcriptional regulator |
| 01/07/2003 | US6504007 GDNF receptor |
| 01/07/2003 | US6504005 Long-acting drugs and pharmaceutical compositions comprising them |
| 01/07/2003 | US6503947 Method of treating cytotoxic damage |
| 01/07/2003 | US6503888 AAV-mediated delivery of DNA to cells of the nervous system |
| 01/07/2003 | US6503887 Peroral gene therapy of diabetes and obesity |
| 01/07/2003 | US6503886 Gene delivery; polypeptide conjugated to fibroblast growth factor fused to nucleic acid |
| 01/07/2003 | US6503881 Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |